- Home
- / Astria Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Astria Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$12
2024-10-29
Market Capitalization
$683.3 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 500.0K | |||||||||
| General and administrative expense | 8.6M | 10.1M | 8.9M | 9.3M | 8.8M | 11.8M | 14.8M | 19.2M | 25.7M | 34.5M |
| Operating expense total | 31.7M | 35.6M | 27.6M | 26.4M | 27.1M | 37.4M | 53.5M | 111.6M | ||
| EBIT | (31.7M) | (35.6M) | (27.1M) | (26.4M) | (27.1M) | (37.4M) | (195.0M) | (53.5M) | (83.0M) | (111.6M) |
| EBIT margin, % | -5418.8% | |||||||||
| Interest income | 242.0K | 160.0K | 425.0K | 845.0K | 236.0K | 122.0K | 1.7M | 10.2M | 17.4M | |
| Interest expense | 971.0K | 502.0K | 270.0K | 501.0K | ||||||
| Net Income | (32.6M) | (36.1M) | (27.4M) | (25.9M) | (26.3M) | (37.3M) | (194.9M) | (51.8M) | (72.9M) | (94.3M) |
| EPS | (3.5) | (2.0) | (1.7) |